Results 121 to 130 of about 661,753 (260)

NAPRT loss promotes lung tumor initiation and growth through AKT signaling independently of NAD+ biosynthesis

Molecular Oncology, EarlyView.
Loss of NAPRT promotes lung tumor initiation and growth through a noncanonical mechanism, independent of its role in NAD+ biosynthesis. Mechanistically, NAPRT depletion activates the mTORC2‐driven AKT/β‐catenin signaling axis to enhance clonogenic and invasive phenotypes. Furthermore, lung‐specific Naprt deletion significantly increases tumor burden in
Myung Joon Oh, Ji Yun Jang, Yoon Jeon, Gi‐Cheon Kim, Hwanho Lee, Jooyoung Lee, Ju‐Hwa Kim, Hakhyun Kim, Minjee Kim, Ho‐Keun Kwon, Ho Lee, Hyun Seok Kim   +11 more
wiley   +1 more source

Discovery and optimization of marstacimab, a human monoclonal antibody targeting tissue factor pathway inhibitor for the treatment of hemophilia A and B. [PDF]

MAbs
Jin M, Hett S, Jasuja R, Rakhe S, Narula J, Tam A, Apgar JR, Juo ZS, Mosyak L, Holsti M, Joyce A, Hurst S, Webster R, Lin L, Stahl M, Pittman DD, Bloom L.   +16 more
europepmc   +1 more source

Platelet tissue factor pathway inhibitor-α dampens cardiac thrombosis and associated fibrosis in mice. [PDF]

J Thromb Haemost, 2023
Maroney SA, Siebert AE, Martinez ND, Rasmussen M, Peterson JA, Weiler H, Lincoln J, Mast AE.   +7 more
europepmc   +1 more source

Regulation of the lncRNA NEAT1 by p53‐ΔNp63 crosstalk modulates the DNA damage response and therapeutic efficacy in HNSCC

Molecular Oncology, EarlyView.
In head and neck squamous cell carcinoma (HNSCC) p53 and p63 exert opposite roles on the transcription regulation of the lncRNA NEAT1. Under basal conditions, p53 levels are low and p63 represses NEAT1 expression. Upon genotoxic stress, p53 is rapidly induced, displacing p63 from the NEAT1 promoter leading to NEAT1 transcriptional activation and ...
Sara De Domenico, Veronica La Banca, Silvia D'Amico, Stefano Scalera, Sara Nicolai, Angelo Peschiaroli   +5 more
wiley   +1 more source

Tissue Factor Pathway Inhibitor [PDF]

, 2020
openaire   +1 more source

An Ex Vivo Pharmacodynamic Study of KN057, a Tissue Factor Pathway Inhibitor Neutralizing Antibody, in Plasma Samples From Patients With Haemophilia or VWD3. [PDF]

Haemophilia
Ju M, Xue F, Sun W, Li F, Xu T, Yang R.
europepmc   +1 more source

Regulation of coagulation by tissue factor pathway inhibitor: Implications for hemophilia therapy. [PDF]

J Thromb Haemost, 2022
Mast AE, Ruf W.
europepmc   +1 more source

Paclitaxel induces NM2‐dependent cellular contraction through GEF‐H1 dissociation from microtubules and RhoA/ROCK activation in cancer cells

Molecular Oncology, EarlyView.
Taxanes are widely used chemotherapeutics whose effects on cellular mechanics remain poorly understood. We show that paclitaxel induces rapid cellular contraction by promoting GEF‐H1 dissociation from microtubules and non‐muscle myosin II activation through RhoA/ROCK.
Gloria Asensio‐Juárez, Rafael Pérez‐Díaz, Hugo Ramos‐Solano, Marina Garrido‐Casado, Vanessa C. Talayero, Miguel Vicente‐Manzanares   +5 more
wiley   +1 more source

Plasma Tissue Factor Pathway Inhibitor Levels Correlate with Disease Activity and Are Associated with Altered Thrombin Generation in Pediatric Inflammatory Bowel Disease. [PDF]

Pharmaceuticals (Basel)
Meyer A, Kohlmaier B, Bauer T, Gallistl S, Muntean W, Silbernagel B, Haidl H, Schlagenhauf A.   +7 more
europepmc   +1 more source

A phase 1b/2 clinical study of marstacimab, targeting human tissue factor pathway inhibitor, in haemophilia. [PDF]

Br J Haematol, 2023
Mahlangu JN, Lamas JL, Morales JC, Malan DR, Šalek SZ, Wang M, Boggio LN, Hegemann I, Mital A, Cardinal M, Zhu T, Sun P, Arkin S.   +12 more
europepmc   +1 more source